DUBLIN–(BUSINESS WIRE)–Aug 23, 2021–
Fuchs Endothelial Corneal Dystrophy (FECD) (Ophthalmology) – Drugs in Development, 2021 provides an overview of the Fuchs Endothelial Corneal Dystrophy (FECD) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Fuchs Endothelial Corneal Dystrophy (FECD), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fuchs Endothelial Corneal Dystrophy (FECD) and features dormant and discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- Gain strategically significant competitor information, analysis, and insights to formulate effective Research and Development (R&D) strategies.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Identify and understand important and diverse types of therapeutics under development for Fuchs Endothelial Corneal Dystrophy (FECD) (Ophthalmology).
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan Mergers and Acquisitions (M&A) effectively by identifying key players and it’s most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding Fuchs Endothelial Corneal Dystrophy (FECD) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
- Report Coverage
- Indication – Overview
- Indication – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Indication – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Indication – Companies Involved in Therapeutics Development
- Indication – Drug Profiles
- Product Description
- Mechanism of Action
- R&D Progress
- Indication – Dormant Projects
- Indication – Discontinued Products
- Indication – Product Development Milestones
- Featured News & Press Releases
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH OPTICAL
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 08/23/2021 11:51 AM/DISC: 08/23/2021 11:51 AM